Modus Therapeutics Holding AB is a biotechnology company based in Stockholm, Sweden, established in 2011. The company focuses on developing treatments for severe systemic inflammation, with an emphasis on conditions like sepsis and septic shock. Its lead product, Sevuparin, is a polysaccharide that is currently in Phase IIa clinical trials. This product targets several medical conditions, including sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, and severe malaria. In July 2021, Modus Therapeutics went public on the First North Stockholm exchange, raising approximately 33 million SEK with the ticker symbol MODTX. The company's market capitalization is around 45 million SEK, and it employs two people. Dr. John Öhd serves as the CEO of the company. More information can be found on their website at www.modustx.com.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
Modus Therapeutics Holding AB's offering is currently approved on OTHER. Modus Therapeutics Holding AB is headquartered in Sweden. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Modus Therapeutics Holding AB.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/modus-therapeutics-holding-ab" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Modus Therapeutics Holding AB — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/modus-therapeutics-holding-ab?theme=light as the src instead.
https://www.discoveripo.com/ipo/modus-therapeutics-holding-ab/opengraph-image
Modus Therapeutics Holding AB IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/modus-therapeutics-holding-ab?utm_source=embed&utm_medium=text&utm_campaign=modus-therapeutics-holding-ab
Get emailed when Modus Therapeutics Holding AB's terms, price, or expected date change — no weekly noise, just this company.
Modus Therapeutics Holding AB is listing on OTHER.
Modus Therapeutics Holding AB is a biotechnology company based in Stockholm, Sweden, established in 2011. The company focuses on developing treatments for severe systemic inflammation, with an emphasis on conditions like sepsis and septic shock. Its lead product, Sevuparin, is a polysaccharide that is currently in Phase IIa clinical trials. This product targets several medical conditions, including sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, and severe malaria. In July 2021, Modus Therapeutics went public on the First North Stockholm exchange, raising approximately 33 million SEK with the ticker symbol MODTX. The company's market capitalization is around 45 million SEK, and it employs two people. Dr. John Öhd serves as the CEO of the company. More information can be found on their website at www.modustx.com.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy